Top

Supportive Care in Cancer

Published in:

01-11-2017 | Original Article

Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial

Authors: C. Riese, B. Weiß, U. Borges Jr, A. Beylich, R. Dengler, K. Hermes-Moll, M. Welslau, W. Baumann

Published in: Supportive Care in Cancer | Issue 11/2017

Abstract

Purpose

Oral agents for cancer treatment are increasingly prescribed due to their benefits. However, oral cancer medications are difficult to handle and have a considerable potential for side effects. This type of therapy requires a high level of self-management competence by the patient. A standardized patient education program provided by physicians and oncology nurses may positively influence the handling of oral agents. The aim of the study was to evaluate the impact of a standardized patient education program provided by specially trained oncology nurses on therapy management regarding side effects and unplanned therapy interruptions.

Methods

One hundred sixty-five patients from 28 office-based oncology practices from all over Germany participated in this cluster-randomized controlled study. Patients of both intervention (n = 111) and standard care groups (n = 54) received the usual oncologist counseling; in addition, the patients from the intervention group (k = 17 practices) received an education from specially trained oncology nurses. The time of observation was 3 months per patient.

Results

The patients of the intervention group reported fewer side effects (skin rash, pain, fatigue, nausea, vomiting). Patients in the standard care group interrupted the therapy more frequently without informing their oncologist, compared to the intervention group.

Conclusions

Patients benefit from a standardized patient education program provided by specially trained oncology nurses. They tend to handle side effects and critical situations better.

May P, Figgins B (2016) Oral anticancer therapy: a comprehensive assessment of patient perceptions and challenges. J Community Support Oncol:112–116View Article
Shah N, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers JS (2015) Improving the safety of oral chemotherapy at an academic medical center. J Oncol Pract. doi:10.1200/JOP.2015.007260 View Article
Banna GL, Collova E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferraù F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat rev 36(8):595–605View Article
Baumann, W (2014) Qualitätsbericht der onkologischen Schwerpunktpraxen 2014. BNHO – Berufsverband der Niedergelassenen Hämatologen und Onkologen 2015, Köln
Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Saika K, Sobue T, Matsuo K (2012) Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist 17(12):1547–1550View Article
Bordonaro S, Raiti F, Di Mari A, Lopiano C, Romano F, Pumo V, Giuliano SR, Iacono M, Lanteri E, Puzzo E, Spada S, Tralongo P (2012) Active home-based cancer treatment. J Multidiscip Healthc 5:137–143. doi:10.2147/JMDH.S31494 View ArticlePubMedPubMed Central
Overkamp F (2015) Herausforderungen zielgerichteter Substanzen an die onkologische Supportivtherapie. Onkologe 21:297–304. doi:10.1007/s00761-014-2795-y View Article
Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20:1907–1912. doi:10.1093/annonc/mdp369 View ArticlePubMed
Barth J, Schelenz C (2011) Orale Tumortherapie—DO’s and DON’Ts. Onkologische Pharmazie 13.3(2011):14–23
Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol 76(2):133–141. doi:10.1016/j.critrevonc.2009.11.001 View ArticlePubMed
Molassiotes A, Brearley S, Saunders M, Craven O, Wardley A, Farrell C, Swindell R, Todd C, Luker K (2009) Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 27:6191–6198. doi:10.1200/JCO.2008.20.6755 View Article
Birner A (2003) Safe administration of oral chemotherapy. Clin J Oncol Nurs 7:158–162. doi:10.1188/03.CJON.158-162 View ArticlePubMed
Miaskowski C, Shockney L, Chlebowski RT (2008) Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs 12:213–221. doi:10.1188/08. CJON.213-221 View ArticlePubMed
Kav S, Johnson J, Rittenberg C, Fernadez-Ortega P, Suominen T, Olsen PR, Patiraki E, Porock D, Dahler A, Toliusiene J, Tadic D, Pittayapan P, Roy V, Wang Q, Colak M, Saca-Hazboun H, Makumi D, Kadmon I, Ami SB, Anderson E, Clark-Snow R (2008) Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer 16:1075–1083. doi:10.1007/s00520-007-0377-x View ArticlePubMed
Bordonaro S, Romano F, Lateri E, Cappuccio F, Indorato R, Butera A, D’Angelo A, Ferraú F, Tralongo P (2014) Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. Patient Preferences Adherence 8:917–923View Article
Chau I, Legge S, Fumoleau P (2004) The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8(Suppl 1):41–53. doi:10.1016/j.ejon.2004.06.008 View Article
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med 363:733–742. doi:10.1056/NEJMoa1000678 View ArticlePubMed
Campbell C (2016) An oral cancer therapy nurse navigator role. Canadian Nurse. https://www.canadian-nurse.com/en/articles/issues/2016/april-2016/an-oral-cancer-therapy-nurse-navigator-role. Accessed 12 July 2016
Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ (2004) Patterns of intra-cluster correlation from primary care research to inform study design and analysis. J Clin Epidemiol 57:785–794. doi:10.1016/j.jclinepi.2003.12.013 View ArticlePubMed
Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C (2010) Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer 18:583–590. doi:10.1007/s00520-009-0692-5 View ArticlePubMed
Long JS, Freese J (2014) Regression models for categorical dependent variables using stata, Third edn. Stata Press Publication, StataCorp LP, College Station (Texas)
R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
McCorkle R, Strumpf NE, Nuamah IF, Adler DC, Cooley ME, Jepson C, Lusk EJ, Torosian M (2000) A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 48:1707–1713View Article
Haslbeck J (2008) Bewältigung komplexer Medikamentenregime aus Sicht chronisch Kranker. Pflege Gesellschaft 13(1):48–61
Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2015) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. Journal of Clinical Oncology JCO630830. doi:10.1200/JCO.2015.63.0830 View Article
Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847–853. doi:10.1002/cncr.23621 View ArticlePubMedPubMed Central
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, Group O behalf of the E.G.W (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232–243. doi:10.1093/annonc/mdq194 View Article
Macedo LT, Lima JPN, dos Santos LV, Sasse AD (2014) Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 22:1585–1593. doi:10.1007/s00520-014-2129-z View ArticlePubMed
Wood L (2012) A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 16:432–438. doi:10.1016/j.ejon.2011.10.002 View ArticlePubMed
Miranda V, Fede A, Nobuo M, Ayres V, Giglio A, Miranda M, Riechelmann RP (2011) Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manag 42:342–353. doi:10.1016/j.jpainsymman.2010.11.014 View Article

Title: Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial
Authors: C. Riese
B. Weiß
U. Borges Jr
A. Beylich
R. Dengler
K. Hermes-Moll
M. Welslau
W. Baumann
Publication date: 01-11-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3770-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2017

Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study

Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer

Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan

The impact of breast cancer treatments on sleep quality 1 year after cancer diagnosis

Psychometric testing of the Mandarin version of the 34-item Short-Form Supportive Care Needs Survey in patients with cancer in mainland China

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer